Acalabrutinib in combination with anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Study identifier:ACE-CL-003

ClinicalTrials.gov identifier:NCT02296918

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 1b Study of ACP-196 in Combination with Obinutuzumab for Patients with Relapsed / Refractory or Untreated CLL/SLL/PLL

Medical condition

Chronic Lymphocytic Leukemia

Phase

Phase 1

Healthy volunteers

No

Study drug

acalabrutinib, Obinutuzumab, Venetoclax, Rituximab

Sex

All

Actual Enrollment

69

Study type

Interventional

Age

N/A

Date

Study Start Date: 22 Dec 2014
Primary Completion Date: 20 Aug 2021
Estimated Study Completion Date: 06 Sept 2027

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

-

Inclusion and exclusion criteria